Nomura Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$223M Buy
1,024,824
+42
+0% +$9.32K 0.57% 27
2025
Q4
$234M Sell
1,024,782
-77,737
-7% -$17.7M 0.59% 22
2025
Q3
$255M Sell
1,102,519
-80,369
-7% -$16.4M 0.67% 18
2025
Q2
$220M Sell
1,182,888
-65,941
-5% -$12.3M 0.6% 23
2025
Q1
$262M Buy
1,248,829
+70,360
+6% +$13.7M 0.8% 18
2024
Q4
$209M Buy
1,178,469
+95,711
+9% +$17.6M 0.63% 21
2024
Q3
$214M Buy
1,082,758
+103,590
+11% +$19.3M 0.66% 20
2024
Q2
$168M Buy
979,168
+22,849
+2% +$3.78M 0.57% 24
2024
Q1
$174M Sell
956,319
-14,435
-1% -$2.49M 0.63% 22
2023
Q4
$150M Buy
970,754
+12,895
+1% +$1.88M 0.62% 27
2023
Q3
$143M Buy
957,859
+65,758
+7% +$9.65M 0.67% 22
2023
Q2
$120M Buy
892,101
+51,320
+6% +$7.53M 0.55% 33
2023
Q1
$134M Buy
840,781
+31,108
+4% +$4.76M 0.7% 22
2022
Q4
$131M Sell
809,673
-45,695
-5% -$7.01M 0.76% 22
2022
Q3
$115M Buy
855,368
+159,480
+23% +$22.9M 0.73% 21
2022
Q2
$107M Sell
695,888
-15,708
-2% -$2.4M 0.67% 24
2022
Q1
$115M Sell
711,596
-28,788
-4% -$4.18M 0.63% 25
2021
Q4
$100M Buy
740,384
+97,243
+15% +$11.5M 0.51% 32
2021
Q3
$69.4M Sell
643,141
-60,691
-9% -$6.93M 0.39% 59
2021
Q2
$79.3M Buy
703,832
+15,704
+2% +$1.77M 0.46% 44
2021
Q1
$74.5M Sell
688,128
-20,702
-3% -$2.21M 0.47% 42
2020
Q4
$76M Buy
708,830
+94,333
+15% +$9.07M 0.51% 41
2020
Q3
$53.8M Buy
614,497
+31,519
+5% +$2.97M 0.41% 54
2020
Q2
$57.2M Buy
582,978
+73,445
+14% +$6.47M 0.48% 47
2020
Q1
$38.8M Buy
509,533
+59,835
+13% +$5.1M 0.4% 61
2019
Q4
$39.8M Buy
449,698
+11,889
+3% +$987K 0.36% 66
2019
Q3
$33.2M Buy
437,809
+47,190
+12% +$3.24M 0.32% 73
2019
Q2
$28.4M Buy
390,619
+9,649
+3% +$758K 0.28% 79
2019
Q1
$30.7M Buy
380,970
+3,912
+1% +$320K 0.3% 79
2018
Q4
$34.8M Buy
377,058
+14,520
+4% +$1.28M 0.39% 64
2018
Q3
$34.3M Buy
362,538
+14,040
+4% +$1.33M 0.33% 70
2018
Q2
$32.3M Sell
348,498
-7,085
-2% -$692K 0.34% 67
2018
Q1
$33.7M Buy
355,583
+28,125
+9% +$3.09M 0.37% 66
2017
Q4
$31.7M Sell
327,458
-17,899
-5% -$1.69M 0.37% 65
2017
Q3
$30.7M Sell
345,357
-82,542
-19% -$6.28M 0.4% 63
2017
Q2
$31M Sell
427,899
-509
-0.1% -$34.2K 0.42% 61
2017
Q1
$27.9M Sell
428,408
-21,008
-5% -$1.32M 0.39% 65
2016
Q4
$28.1M Sell
449,416
-19,265
-4% -$1.18M 0.51% 45
2016
Q3
$29.6M Sell
468,681
-34,413
-7% -$2.23M 0.53% 44
2016
Q2
$31.1M Sell
503,094
-50,552
-9% -$3.08M 0.58% 40
2016
Q1
$31.6M Buy
553,646
+40,464
+8% +$2.26M 0.6% 39
2015
Q4
$30.4M Buy
513,182
+34,088
+7% +$1.96M 0.59% 40
2015
Q3
$26.1M Sell
479,094
-27,011
-5% -$1.76M 0.52% 49
2015
Q2
$34M Sell
506,105
-35,152
-6% -$2.29M 0.63% 37
2015
Q1
$31.7M Sell
541,257
-224,958
-29% -$13.6M 0.56% 44
2014
Q4
$50.6M Buy
766,215
+25,558
+3% +$1.61M 0.88% 16
2014
Q3
$42.8M Buy
740,657
+1,560
+0.2% +$86.6K 0.76% 26
2014
Q2
$41.7M Buy
739,097
+64,080
+9% +$3.36M 0.77% 22
2014
Q1
$34.7M Buy
675,017
+443,415
+191% +$22.4M 0.63% 34
2013
Q4
$12.2M Sell
231,602
-227,650
-50% -$11.2M 0.22% 122
2013
Q3
$20.5M Sell
459,252
-57,540
-11% -$2.55M 0.39% 64
2013
Q2
$21.4M Buy
+516,792
New +$22.6M 0.42% 47

Other funds holding ABBV

Nomura Asset Management's ABBV Position: Q1 2026 in Review

Nomura Asset Management increased its AbbVie (ABBV) stake by 0% in Q1 2026, buying an estimated $9.32K and bringing the position to 1,024,824 shares worth $223M. The position accounts for 0.57% of the portfolio, ranked #27.

Nomura Asset Management first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $262M in Q1 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Nomura Asset Management held 1,024,824 shares of AbbVie worth $223M as of Q1 2026.
  • Nomura Asset Management bought 42 AbbVie shares in Q1 2026, an estimated $9.32K.
  • AbbVie made up 0.57% of Nomura Asset Management's portfolio in Q1 2026, its #27 holding.
  • Nomura Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Nomura Asset Management's AbbVie position peaked at $262M in Q1 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Nomura Asset Management's 13F filing for Q1 2026, filed 11 May 2026.